{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:39:52Z","timestamp":1715906392417},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"DOI":"10.7759\/cureus.60377","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:26:08Z","timestamp":1715826368000},"source":"Crossref","is-referenced-by-count":0,"title":["Cytoplasmic PPAR\u03b3 Significantly Correlates With P53 Immunohistochemical Expression and Tumor Size in Localized Tenosynovial Giant Cell Tumor"],"prefix":"10.7759","author":[{"given":"Fatma Alzahraa A","family":"Elkhamisy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elshaimaa A","family":"Aboelkomsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa K","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed N","family":"Eesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Tenosynovial giant cell tumour","author":"De Saint Aubain Somerhausen N","year":"2020","unstructured":"De Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour. WHO Classification of Tumours: Soft Tissue and Bone Tumours. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (ed): IARC Press, Lyon, France; 2020. 3:133-6."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820046","article-title":"Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features","volume":"13","author":"Robert M","year":"2022","unstructured":"Robert M, Farese H, Miossec P. Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front Immunol. 2022, 13:820046. 10.3389\/fimmu.2022.820046","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01883-5","article-title":"Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry","volume":"16","author":"Lopez-Bastida J","year":"2021","unstructured":"Lopez-Bastida J, Aranda-Reneo I, Rodr\u00edguez-S\u00e1nchez B, et al.. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet J Rare Dis. 2021, 16:294. 10.1186\/s13023-021-01883-5","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000002159","article-title":"The economic burden of tenosynovial giant cell tumors among employed workforce in the United States","volume":"63","author":"Lin F","year":"2021","unstructured":"Lin F, Ionescu-Ittu R, Pivneva I, et al.. The economic burden of tenosynovial giant cell tumors among employed workforce in the United States. J Occup Environ Med. 2021, 63:e197-202. 10.1097\/JOM.0000000000002159","journal-title":"J Occup Environ Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom MJ","year":"2017","unstructured":"Mastboom MJ, Verspoor FG, Verschoor AJ, et al.. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017, 88:688-94. 10.1080\/17453674.2017.1361126","journal-title":"Acta Orthop"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein V","year":"2017","unstructured":"Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R, Acquavella JF. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017, 44:1476-83. 10.3899\/jrheum.160816","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12593-015-0185-3","article-title":"Multiple giant cell tumors of the tendon sheath: separate volar and dorsal lesions involving three digits of the same hand following repetitive trauma","volume":"7","author":"Kerfant N","year":"2015","unstructured":"Kerfant N, Bardin T, Roulot E. Multiple giant cell tumors of the tendon sheath: separate volar and dorsal lesions involving three digits of the same hand following repetitive trauma. J Hand Microsurg. 2015, 7:233-5. 10.1007\/s12593-015-0185-3","journal-title":"J Hand Microsurg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37600","article-title":"Multi-focal giant cell tumor of a single tendon sheath: a rare case report","volume":"15","author":"Novick SD","year":"2023","unstructured":"Novick SD, Kahlon P, Berhanu M, Patel P, Uderani M, Saleem F. Multi-focal giant cell tumor of a single tendon sheath: a rare case report. Cureus. 2023, 15:e37600. 10.7759\/cureus.37600","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2067040","article-title":"Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches","volume":"26","author":"Spierenburg G","year":"2022","unstructured":"Spierenburg G, van der Heijden L, van Langevelde K, Szuhai K, Bov\u00e9e JVGM, van de Sande MAJ, Gelderblom H. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches. Expert Opin Ther Targets. 2022, 26:333-45. 10.1080\/14728222.2022.2067040","journal-title":"Expert Opin Ther Targets"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2017.03.016","article-title":"Giant cell tumor of tendon sheath: open surgery or arthroscopic synovectomy? A systematic review of the literature","volume":"103","author":"Noailles T","year":"2017","unstructured":"Noailles T, Brulefert K, Briand S, Longis PM, Andrieu K, Chalopin A, Gouin F. Giant cell tumor of tendon sheath: open surgery or arthroscopic synovectomy? A systematic review of the literature. Orthop Traumatol Surg Res. 2017, 103:809-14. 10.1016\/j.otsr.2017.03.016","journal-title":"Orthop Traumatol Surg Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260795","article-title":"Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle\u2014a systematic review and meta-analysis","volume":"16","author":"Siegel M","year":"2021","unstructured":"Siegel M, Bode L, S\u00fcdkamp N, K\u00fchle J, Zwingmann J, Schmal H, Herget GW. Treatment, recurrence rates and follow-up of tenosynovial giant cell tumor (TGCT) of the foot and ankle\u2014a systematic review and meta-analysis. PLoS One. 2021, 16:e0260795. 10.1371\/journal.pone.0260795","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0287028","article-title":"Prediction of local recurrence in tenosynovial giant cell tumor of the knee: based on preoperative MRI evaluation into disease subtypes and severity","volume":"18","author":"Kim JH","year":"2023","unstructured":"Kim JH, Lee SK, Kim JY. Prediction of local recurrence in tenosynovial giant cell tumor of the knee: based on preoperative MRI evaluation into disease subtypes and severity. PLoS One. 2023, 18:e0287028. 10.1371\/journal.pone.0287028","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles M","year":"2021","unstructured":"Hernandez-Quiles M, Broekema MF, Kalkhoven E. PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action. Front Endocrinol (Lausanne). 2021, 12:624112. 10.3389\/fendo.2021.624112","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737776","article-title":"PPAR-\u03b3 modulators as current and potential cancer treatments","volume":"11","author":"Chi T","year":"2021","unstructured":"Chi T, Wang M, Wang X, Yang K, Xie F, Liao Z, Wei P. PPAR-\u03b3 modulators as current and potential cancer treatments. Front Oncol. 2021, 11:737776. 10.3389\/fonc.2021.737776","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.900010","article-title":"Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: the REALIZE study","volume":"12","author":"Takeuchi A","year":"2022","unstructured":"Takeuchi A, Endo M, Kawai A, et al.. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: the REALIZE study. Front Oncol. 2022, 12:900010. 10.3389\/fonc.2022.900010","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0252","article-title":"Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation","volume":"14","author":"Huang HY","year":"2008","unstructured":"Huang HY, West RB, Tzeng CC, et al.. Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: the potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clin Cancer Res. 2008, 14:6023-32. 10.1158\/1078-0432.CCR-08-0252","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04697-w","article-title":"Sirt1 inhibits gouty arthritis via activating PPAR\u03b3","volume":"38","author":"Wang J","year":"2019","unstructured":"Wang J, Chen G, Lu L, Zou H. Sirt1 inhibits gouty arthritis via activating PPAR\u03b3. Clin Rheumatol. 2019, 38:3235-42. 10.1007\/s10067-019-04697-w","journal-title":"Clin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00957-9","article-title":"PPAR-\u03b3 alleviates the inflammatory response in TNF-\u03b1-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis","volume":"44","author":"Li XF","year":"2023","unstructured":"Li XF, Yin SQ, Li H, et al.. PPAR-\u03b3 alleviates the inflammatory response in TNF-\u03b1-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis. Acta Pharmacol Sin. 2023, 44:454-64. 10.1038\/s41401-022-00957-9","journal-title":"Acta Pharmacol Sin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316339","article-title":"PPAR\u03b3-p53-mediated Vasculoregenerative program to reverse pulmonary hypertension","volume":"128","author":"Hennigs JK","year":"2021","unstructured":"Hennigs JK, Cao A, Li CG, et al.. PPAR\u03b3-p53-mediated Vasculoregenerative program to reverse pulmonary hypertension. Circ Res. 2021, 128:401-18. 10.1161\/CIRCRESAHA.119.316339","journal-title":"Circ Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0432","article-title":"Acetylated-PPAR\u03b3 expression is regulated by different P53 genotypes associated with the adipogenic differentiation of polyploid giant cancer cells with daughter cells","volume":"20","author":"Zhang K","year":"2023","unstructured":"Zhang K, Yang X, Zheng M, Ning Y, Zhang S. Acetylated-PPAR\u03b3 expression is regulated by different P53 genotypes associated with the adipogenic differentiation of polyploid giant cancer cells with daughter cells. Cancer Biol Med. 2023, 20:56-76. 10.20892\/j.issn.2095-3941.2022.0432","journal-title":"Cancer Biol Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0057-0","article-title":"Principles and approaches for reproducible scoring of tissue stains in research","volume":"98","author":"Meyerholz DK","year":"2018","unstructured":"Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018, 98:844-55. 10.1038\/s41374-018-0057-0","journal-title":"Lab Invest"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245638","article-title":"Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images","volume":"16","author":"Ram S","year":"2021","unstructured":"Ram S, Vizcarra P, Whalen P, et al.. Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images. PLoS One. 2021, 16:e0245638. 10.1371\/journal.pone.0245638","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-022-05681-3","article-title":"Evaluation of the expression pattern and diagnostic value of PPAR\u03b3 in malignant and benign primary bone tumors","volume":"23","author":"Eghtedari AR","year":"2022","unstructured":"Eghtedari AR, Vaezi MA, Safizadeh B, Ghasempour G, Babaheidarian P, Salimi V, Tavakoli-Yaraki M. Evaluation of the expression pattern and diagnostic value of PPAR\u03b3 in malignant and benign primary bone tumors. BMC Musculoskelet Disord. 2022, 23:746. 10.1186\/s12891-022-05681-3","journal-title":"BMC Musculoskelet Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.3465","article-title":"Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol","volume":"9","author":"Crowe AR","year":"2019","unstructured":"Crowe AR, Yue W. Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol. Bio Protoc. 2019, 9:e3465. 10.21769\/BioProtoc.3465","journal-title":"Bio Protoc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602678","article-title":"Reporting recommendations for tumour marker prognostic studies (REMARK)","volume":"93","author":"McShane LM","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer. 2005, 93:387-91. 10.1038\/sj.bjc.6602678","journal-title":"Br J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001071","article-title":"Lessons learned, challenges taken, and actions made for \u201cprecision\u201d immunohistochemistry. Analysis and perspectives from the NordiQC Proficiency Testing Program","volume":"31","author":"Nielsen S","year":"2023","unstructured":"Nielsen S, Bzorek M, Vyberg M, R\u00f8ge R. Lessons learned, challenges taken, and actions made for \u201cprecision\u201d immunohistochemistry. Analysis and perspectives from the NordiQC Proficiency Testing Program. Appl Immunohistochem Mol Morphol. 2023, 31:452-8. 10.1097\/PAI.0000000000001071","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref27","article-title":"Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts","volume":"150","author":"Darling JM","year":"1997","unstructured":"Darling JM, Goldring SR, Harada Y, Handel ML, Glowacki J, Gravallese EM. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. Am J Pathol. 1997, 150:1383-93.","journal-title":"Am J Pathol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.288","article-title":"Research trends in pharmacological modulation of tumor-associated macrophages","volume":"11","author":"Wang N","year":"2021","unstructured":"Wang N, Wang S, Wang X, et al.. Research trends in pharmacological modulation of tumor-associated macrophages. Clin Transl Med. 2021, 11:e288. 10.1002\/ctm2.288","journal-title":"Clin Transl Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHARMTHERA.2020.107521","article-title":"Pharmacological targets of metabolism in disease: opportunities from macrophages","volume":"210","author":"Castegna A","year":"2020","unstructured":"Castegna A, Gissi R, Menga A, Montopoli M, Favia M, Viola A, Canton M. Pharmacological targets of metabolism in disease: opportunities from macrophages. Pharmacol Ther. 2020, 210:107521. 10.1016\/J.PHARMTHERA.2020.107521","journal-title":"Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2021.2469","article-title":"Overexpression of the PPAR-\u03b3 protein in primary Ta\/T1 non-muscle-invasive urothelial carcinoma","volume":"16","author":"Tanaka S","year":"2022","unstructured":"Tanaka S, Tokuhara Y, Hosokawa S, et al.. Overexpression of the PPAR-\u03b3 protein in primary Ta\/T1 non-muscle-invasive urothelial carcinoma. Mol Clin Oncol. 2022, 16:36. 10.3892\/mco.2021.2469","journal-title":"Mol Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245400-cytoplasmic-ppar-significantly-correlates-with-p53-immunohistochemical-expression-and-tumor-size-in-localized-tenosynovial-giant-cell-tumor","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:26:12Z","timestamp":1715826372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245400-cytoplasmic-ppar-significantly-correlates-with-p53-immunohistochemical-expression-and-tumor-size-in-localized-tenosynovial-giant-cell-tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.60377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}